Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-09-16 Legal Proceedings Report
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
Updates
Legal Proceedings Report Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding the disposal of a legal suit filed by Panacea Biotec Limited against Sanofi Healthcare India Private Limited. It details the settlement agreement reached between the parties and the terms of the settlement, including the withdrawal of oppositions and the agreement not to launch a competing vaccine. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material event disclosures. The content is focused on legal proceedings and their resolution, not on financial results, management changes, or other report types. It is not a full audit report, annual report, earnings release, or any financial report. It is a regulatory announcement about a legal matter and settlement. Therefore, the most appropriate classification is Legal Proceedings Report (LTR). The document length and detail confirm it is not a brief announcement or a certification but a substantive legal update.
2024-09-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a communication from Panacea Biotec Limited to the stock exchanges and shareholders regarding the mandatory registration and updation of PAN and KYC details for shareholders holding shares in physical form. It references SEBI circulars and provides detailed instructions and forms for shareholders to comply with regulatory requirements. The content is primarily an announcement and reminder to shareholders about compliance and does not contain financial statements, audit information, or detailed financial results. It is not a report itself but a regulatory compliance communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-13 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a commitment of a long-term loan of US$20 million from the U.S. International Development Finance Corporation (DFC) to Panacea Biotec Limited for a capacity-expansion project related to their hexavalent vaccine. It is addressed to stock exchanges and includes details about the loan, the vaccine, and the companies involved. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is primarily an announcement of a financing commitment, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (9042 characters) is sufficient to be more than a brief announcement but it is clearly a press release about financing, not a report publication or regulatory filing. Hence, the classification is CAP with high confidence.
2024-09-12 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and depositories providing details about shares dematerialized during August 2024. It references Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and includes a certificate from the Registrar and Transfer Agent (RTA) confirming the dematerialized shares as of August 31, 2024. The document is informational and regulatory in nature, reporting compliance with share dematerialization disclosure requirements. It does not contain financial statements, management discussion, or detailed financial data. The document length is short (3211 characters) and serves as a regulatory compliance update rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-06 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India and BSE Limited regarding compliance under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It encloses copies of a newspaper advertisement about the Notice of the 40th Annual General Meeting (AGM), including details such as the cut-off date, remote e-voting information, and book closure. The letter is dated September 6, 2024, and is signed by the Group CFO and Company Secretary. The content is primarily an announcement of the publication of the AGM notice in newspapers, not the AGM materials themselves or the meeting minutes. The document is about informing the stock exchanges and the public about the AGM notice publication as required by listing regulations. It does not contain the AGM presentation or detailed materials but is a compliance announcement. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to compliance and notice publication, not the AGM information itself (AGM-R). The document length is 15,000 characters, but the content is a formal letter and notice publication announcement, not the full AGM materials.
2024-09-06 English
Book Closure
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the book closure dates for equity shares. It references Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to the process of closing the register of members for the purpose of holding the Annual General Meeting (AGM). The document specifies the book closure period and the date of the 40th AGM. It does not contain financial statements, detailed financial data, or management discussion, nor does it announce voting results or provide proxy solicitation materials. Instead, it is an announcement related to the administrative process for the AGM, specifically the book closure notice. Such notices are typically classified under Regulatory Filings (RNS) as they are regulatory compliance communications that do not fit into more specific categories like AGM Information or Declaration of Voting Results. The document length is short (1558 characters), and it is an announcement rather than a report or presentation.
2024-09-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.